NeueHealth Inc (NYSE:NEUE) Reports Mixed Q2 2025 Results: Revenue Misses but EPS Beats Estimates

NeueHealth Inc (NYSE:NEUE) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The company posted revenue of $209.1 million, falling short of the consensus estimate of $300.8 million. Earnings per share (EPS) came in at -$1.68, significantly better than the anticipated -$4.39.

Key Financial Highlights

• Revenue Miss: Reported $209.1M vs. $300.8M estimated (30.5% below expectations).
• EPS Beat: Reported -$1.68 vs. -$4.39 estimated (a narrower loss than projected).
• Adjusted EBITDA: $19.0M for Q2, marking the sixth consecutive quarter of profitability on this metric.
• Value-Based Consumers Served: Increased to 546,000, up from 364,000 in the prior-year period.
• Cash Position: Improved to $131.6M in cash and equivalents, up from $83.3M at the end of 2024.

Market Reaction

The stock showed a modest pre-market decline of -1.98%, suggesting a muted reaction to the earnings release. While the revenue miss is notable, the better-than-expected EPS performance may have tempered negative sentiment. Over the past month, NEUE has seen minimal movement, with a slight gain of 0.07%, indicating that investors remain cautious but not overly bearish.

Outlook vs. Analyst Estimates

The company did not provide explicit forward guidance in its press release. However, analysts currently expect:

• Q3 2025 Revenue: $307.4M
• Q3 2025 EPS: -$3.72
• Full-Year 2025 Revenue: $1.255B
• Full-Year 2025 EPS: -$16.99

Given the revenue shortfall in Q2, NeueHealth will need to demonstrate stronger top-line growth in subsequent quarters to meet full-year expectations.

Press Release Summary

CEO Mike Mikan highlighted the company’s continued momentum in value-based care, with growth across ACA Marketplace, Medicare, and Medicaid segments. The earnings call emphasized progress in NeueHealth’s care enablement platform, which supports clinical and financial operations. The company also noted improved liquidity and a reduction in net loss compared to the prior year.

For a deeper dive into NeueHealth’s earnings and future estimates, visit the earnings page here.

Disclaimer: This article is not investment advice. Investors should conduct their own research before making decisions.